Alphamab Oncology 2022 SR
The report highlights Alphamab Oncology's 2022 progress in innovative anti-tumor drug development, notably the commercial success of ENWEIDA®, which benefited over 20,000 patients. The company established a robust three-level ESG governance structure and achieved significant environmental milestones, including a 63.72% reduction in greenhouse gas emission intensity compared to 2020. Key operational advancements included the implementation of digital quality management systems like LIMS and QMS. Socially, the company emphasized employee development and community welfare, donating 120,000 vials of ENWEIDA® through its patient relief project. The report also details the company's alignment with TCFD recommendations for climate risk management.
Company: Alphamab Oncology
Sector: Manufacturing
Country: China
Year: 2022
Type: SR
Pages: 38
Back to company
Alphamab Oncology
ESG Report
The report highlights Alphamab Oncology's 2022 progress in innovative anti-tumor drug development, notably the commercial success of ENWEIDA®, which benefited over 20,000 patients. The company established a robust three-level ESG governance structure and achieved significant environmental milestones, including a 63.72% reduction in greenhouse gas emission intensity compared to 2020. Key operational advancements included the implementation of digital quality management systems like LIMS and QMS. Socially, the company emphasized employee development and community welfare, donating 120,000 vials of ENWEIDA® through its patient relief project. The report also details the company's alignment with TCFD recommendations for climate risk management.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees